Adis for Authors
Adis is an independent and reputable publisher with a large international readership of healthcare practitioners, researchers and decision makers with an interest in drugs and related areas, including drug delivery mechanisms and diagnostic interventions.
Adis offers expert guidance and personalized support, and your published work will be highly discoverable on Springer Nature's global content platforms.
The reputation of our journals and our author-friendly processes mean that many authors repeatedly return to our journals when seeking to publish their work.
Over 50 years of excellence in publishing, connecting research with a worldwide audience.
If you are interested in submitting a paper to one of our journals, we recommend that you first read the Aims and Scope and Instructions for Authors sections on the individual journal pages on Springer Nature Link. These sections will provide you with information on the type of papers that will be accepted by the title, the layout and format you should follow, and details of our policies and procedures.
Once you are ready to submit a manuscript, you can do this using the Editorial Manager manuscript-tracking system. Select ‘Submit manuscript’ on the relevant journal page to go through to the system. Step-by-step instructions are available on the site.
If you are submitting to an Adis Rapid+ journal, then the Rapid+ team can submit the manuscript on your behalf.
Benefits of publishing with Adis
We understand the needs of authors and researchers involved in drug development, and we offer a rapid and responsive personal service to ensure the right home for all scientifically sound content.
Timely publications
All Adis Journals offer efficient publication timelines, with different options available through our Premier Journals, Rapid+ Journals, and VIP service.
Large and global readership
Adis Journals are available via Springer Nature to thousands of institutions worldwide
Open access content is available to anyone in the world, also on the Springer Nature platform
Readership comprises healthcare practitioners, researchers and decision makers with an interest in drugs or other therapeutic / diagnostic interventions and healthcare outcomes
Personalized author support
Pre-submission inquiries are welcomed, and expert editorial assistance will be provided throughout the publication process
Has a manuscript been rejected after peer review in a different journal? We encourage submitting the manuscript together with previous reviewer comments received, and a letter explaining how these have been addressed – our Editors are happy to discuss the manuscript and identify the perfect vehicle for any scientifically sound article
Article discoverability
Most Adis Journals are PubMed- or Medline-indexed, and all offer open access publishing options
Adis content benefits from the superior search engine optimization and semantic linking afforded by Springer Nature's global content platforms
Flexible publishing options
All articles are published with bulleted key summary points to encourage access to a wider readership
All Adis subscription titles offer open access publication at the author’s choice, and we offer a fully open access portfolio covering many therapeutic areas
Submissions of positive, negative and confirmatory studies welcomed
Independent and unbiased
All submissions are subject to a thorough editorial process to ensure that all Adis-published content is scientifically sound and relevant to our readers. Our editorial boards comprise globally recognised experts in relevant fields.
Adis endorses ICMJE / WAME/ COPE guidelines and codes of conduct for journal Editors and encourages authors of sponsored research to comply with Good Publication Practice (GPP). All submissions are subject to peer review.
Bring your article to life with digital enhancements
Digital features can be published in association with any article in an Adis journal. They provide a concise and clear summary of the manuscript to enhance reader accessibility and the educational value of the article. They can also supplement the data through visualisation or clarify a therapeutic technique.
Digital features can be excellent tools to facilitate understanding of medical content for a wide range of audiences. They can be embedded within eprints, used as training aids, or hosted on scientific congress booths and educational platforms.
Digital Features
Adis Journals offers the option of publishing digital features with articles including (but not limited to):
- Videos
- Animated abstracts
- Slide decks
- Audio slides
- Podcasts
- Infographics
Digital features are designed to increase the visibility, readership and educational value of articles
Plain Language Summaries
Plain language summaries (PLS) can be published with any article; these aim to assist readers who have some knowledge of, but not in-depth expertise in, the article content to further understand its importance and clinical relevance. PLS can be text-based or digital (graphical, animated, etc.).
Peer-Reviewed
All plain language summaries and digital features are peer reviewed to ensure the factual integrity, balance and clear presentation of information. Digital features also include a “Peer reviewed” stampe and the Adis logo to confirm the rigorous scientific review process that all Adis content undergoes. Digital features can also be embedded within an article on SpringerLink, included as supplementary material and/or hosted on Figshare.
Submission Information
We recommend that features are submitted with the parent manuscript to allow simultaneous peer review. However, authors can submit features after manuscript acceptance, or even publication, of an article.
A fee applies to all features, except text-based plain language summaries, if submitted at any point after acceptance to cover the additional editorial processing.
If a feature is submitted after publication of the article, the journal will also be required to publish a Correction notice to inform readers of the post-publication addition of the digital feature and the parent article will not be updated.
